Report Detail
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights, Forecast to 2025
- RnM2946255 |
- 25 April, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is valued at 5240 million US$ in 2018 and will reach 14200 million US$ by the end of 2025, growing at a CAGR of 13.3% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Glucagon Like Peptide-1 (GLP-1) Agonists market based on company, product type, end user and key regions.
This report studies the global market size of Glucagon Like Peptide-1 (GLP-1) Agonists in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Glucagon Like Peptide-1 (GLP-1) Agonists in these regions.
This research report categorizes the global Glucagon Like Peptide-1 (GLP-1) Agonists market by top players/brands, region, type and end user. This report also studies the global Glucagon Like Peptide-1 (GLP-1) Agonists market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Market size by Product
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market size by End User
Hospital
Pharmacy
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Glucagon Like Peptide-1 (GLP-1) Agonists market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Glucagon Like Peptide-1 (GLP-1) Agonists market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Glucagon Like Peptide-1 (GLP-1) Agonists companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Glucagon Like Peptide-1 (GLP-1) Agonists submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Glucagon Like Peptide-1 (GLP-1) Agonists are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Glucagon Like Peptide-1 (GLP-1) Agonists market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Product
- 1.4.2 Exenatied
- 1.4.3 Liraglutide
- 1.4.4 Lixisenatide
- 1.4.5 Albiglutide
- 1.4.6 Dulaglutide
- 1.5 Market by End User
- 1.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Pharmacy
- 1.5.4 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size
- 2.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2014-2025
- 2.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2014-2025
- 2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Growth Rate by Regions
- 2.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Regions
- 2.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers
- 3.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers
- 3.1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers
- 3.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Ratio (CR5 and HHI)
- 3.2 Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers
- 3.2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2014-2019)
- 3.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2014-2019)
- 3.3 Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturers
- 3.4 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution, Product Types
- 3.4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
- 3.4.3 Date of International Manufacturers Enter into Glucagon Like Peptide-1 (GLP-1) Agonists Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product
- 4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Product
- 4.3 Glucagon Like Peptide-1 (GLP-1) Agonists Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Breakdown Data by End User
6 North America
- 6.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists by Countries
- 6.1.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries
- 6.1.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists by Product
- 6.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists by End User
7 Europe
- 7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists by Countries
- 7.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries
- 7.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists by Product
- 7.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists by End User
8 Asia Pacific
- 8.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists by Countries
- 8.1.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries
- 8.1.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists by Product
- 8.3 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists by End User
9 Central & South America
- 9.1 Central & South America Glucagon Like Peptide-1 (GLP-1) Agonists by Countries
- 9.1.1 Central & South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries
- 9.1.2 Central & South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Glucagon Like Peptide-1 (GLP-1) Agonists by Product
- 9.3 Central & South America Glucagon Like Peptide-1 (GLP-1) Agonists by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists by Countries
- 10.1.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries
- 10.1.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists by Product
- 10.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists by End User
11 Company Profiles
- 11.1 Novo Nordisk
- 11.1.1 Novo Nordisk Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 11.1.5 Novo Nordisk Recent Development
- 11.2 AstraZeneca
- 11.2.1 AstraZeneca Company Details
- 11.2.2 Company Business Overview
- 11.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 11.2.5 AstraZeneca Recent Development
- 11.3 Eli Lilly
- 11.3.1 Eli Lilly Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 11.3.5 Eli Lilly Recent Development
- 11.4 GSK
- 11.4.1 GSK Company Details
- 11.4.2 Company Business Overview
- 11.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 11.4.5 GSK Recent Development
- 11.5 Sanofi
- 11.5.1 Sanofi Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 11.5.5 Sanofi Recent Development
- 11.6 Bristol-Myers Squibb
- 11.6.1 Bristol-Myers Squibb Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 11.6.5 Bristol-Myers Squibb Recent Development
- 11.7 Amylin
- 11.7.1 Amylin Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
- 11.7.5 Amylin Recent Development
12 Future Forecast
- 12.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Regions
- 12.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Regions 2019-2025
- 12.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Regions 2019-2025
- 12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Product
- 12.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Product 2019-2025
- 12.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Product 2019-2025
- 12.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by End User
- 12.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Forecast
- 12.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Forecast
- 12.6 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Forecast
- 12.7 Central & South America Glucagon Like Peptide-1 (GLP-1) Agonists Forecast
- 12.8 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Glucagon Like Peptide-1 (GLP-1) Agonists . Industry analysis & Market Report on Glucagon Like Peptide-1 (GLP-1) Agonists is a syndicated market report, published as Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
